SITS Open stroke trial includes pREset Thrombectomy Device by phenox GmbH

pREset Thromectomy Device (helical slit in blue)
(PresseBox) ( Bochum, phenox GmbH, )
phenox GmbH, announces participation in the SITS Open clinical trial where pREset and pREset LITE Thrombectomy Devices have been included in the study device portfolio, one of only three devices to be used in the study.

Stroke is the second leading cause of death worldwide and the most common cause of adult disability in the western world. Ischemic stroke, caused by a blocked artery, is the most common type of stroke and it takes only minutes without oxygen for brain damage to occur and more brain cells die every minute that flow is blocked. The aim of physicians is to restore blood flow by opening the blocked artery as quickly as possible thereby enhancing the patient’s survivability and prevent long lasting disability.

The positive outcomes of recent randomized clinical trials for mechanical thrombectomy such as MR CLEAN, ESCAPE, EXTEND IA and SWIFT PRIME have renewed interest in studies enrolling a large number of patients - studies such as SITS Open. The SITS Open protocol is designed to provide a higher level of evidence for mechanical thrombectomy through a direct comparison between mechanical thrombectomy and a concurrent control of medical management alone.

According to the Department of Neuroscience at Karolinska Institute (Stockholm, Sweden), sponsors of the trial, 194 patients are enrolled in the open, prospective, international, multicenter, controlled clinical trial as of today. The protocol calls for enrolling 600 patients in total, 300 in each arm. Patients enrolled in the treatment arm will be done so at centers that currently perform thrombectomy for stroke and fulfil the quality and training criteria for neuro-interventions. Patients in the control arm will be enrolled by clinics that offer IV thrombolysis and neither practice thrombectomy nor refer patients with ischemic stroke to other clinics where thrombectomy is offered.
phenox’ Managing Director, Dr. –Ing Hermann Monstadt said, “given the growing evidence regarding the effectiveness of mechanical thrombectomy, it is very important that pREset and pREset LT are a part of the tools available to physicians in treating ischemic stroke.”
The publisher indicated in each case is solely responsible for the press releases above, the event or job offer displayed, and the image and sound material used (see company info when clicking on image/message title or company info right column). As a rule, the publisher is also the author of the press releases and the attached image, sound and information material.
The use of information published here for personal information and editorial processing is generally free of charge. Please clarify any copyright issues with the stated publisher before further use. In the event of publication, please send a specimen copy to service@pressebox.de.